IBJNews

Roche scraps hoped-for cholesterol blockbuster

Back to TopCommentsE-mailPrintBookmark and Share

A second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies.

Swiss drugmaker Roche Holding AG said Monday it has halted testing of its dalcetrapib, which the company had hoped would become a blockbuster, with eventual annual sales of more than $1 billion. The drug was in expensive late-stage patient testing as a treatment to raise HDL, or so-called good cholesterol, in heart disease patients.

Basel-based Roche said it decided to pull the plug on the recommendation of its independent data and safety monitoring board after an interim analysis, in a study called dal-OUTCOMES, found no "clinically meaningful" benefit.

The best-known drug in that class, called CETP inhibitors, was Pfizer Inc.'s torcetrapib. It was scrapped five years ago due to safety problems. Merck & Co. and Indianapolis-based Eli Lilly and Co. both are developing drugs in the class. Merck's anacetrapib is in a huge late-stage study, and Lilly's evacetrapib will soon begin late-stage testing.

The CETP class once was seen as successors to the heavily advertised cholesterol-lowering statins taken by tens of millions of people to prevent plaque from building up in arteries and later triggering heart attacks and strokes. Those drugs, which collectively have racked up hundreds of billions of dollars in sales but mostly have generic competition now, include Lipitor and Crestor, plus the older drugs Zocor, Mevacor and Pravachol.

Testing of CETP inhibitors has been among the most expensive drug development programs even though not everyone was convinced they were a good bet, Bernstein Research analyst Dr. Tim Anderson noted Monday.

"Experts in the field of cholesterol management have remained uncertain about the general approach of raising HDL-cholesterol through CETP inhibition. Investors have also remained cautious," Anderson wrote to investors Monday.

Roche, the sixth-biggest drugmaker globally, said that two other late-stage studies of its dalcetrapib have been completed and three other studies were ongoing. Still, the company decided to terminate the drug's entire testing program.

"While we have always stated that dalcetrapib is a high-risk project, we are disappointed by the fact that this drug didn't provide benefit to the patients in our study," Dr. Hal Barron, Roche's chief medical officer and head of global product development, said in a statement, adding that Roche has a robust pipeline and is committed to developing new heart medicines.

Merck spokeswoman Pam Eisley said the company "remains confident in our development program for anacetrapib." A huge study called REVEAL that started last spring is enrolling 30,000 patients to see whether anacetrapib prevents heart attacks and strokes when added to a statin. Results aren't expected for several years. Another late-stage anacetrapib study already completed found it boosted good cholesterol by well over 100 percent and lowered bad cholesterol about 40 percent.

Merck pioneered the statin category with the first drug, Mevacor, and then followed up with Zocor, which was its top seller until generic competition hit in June 2006.

Meanwhile, Lilly said the company is committed to its evacetrapib and plans to start a late-stage study in the second half of this year. Spokeswoman Christina Gaines noted earlier testing showed evacetrapib raises good cholesterol up to 129 percent and reduces bad cholesterol by up to 36 percent, depending on dose.

Statins for years were among the most heavily prescribed drugs in developing countries, where heart disease is a top killer. Pfizer's Lipitor reigned as the top-selling drug in history for about eight years, with peak sales of $13 billion in 2006, but it got limited U.S. generic competition in December. By then, inexpensive generic versions of Zocor and the other older statins already had been nibbling at revenue for Lipitor, which will plunge when multiple generic versions hit drugstores on May 31.

Pfizer, the world's biggest drugmaker, had made it a priority to find a successor before the patent expired on Lipitor, which brought in about a quarter of its revenue from 2004 through 2009. But its heavily touted torcetrapib flamed out early in 2007, after roughly $800 million in testing, because it raised risk of heart attacks and strokes. That failure, along with a general decline in productivity from Pfizer's sprawling research labs, was widely seen as among the reasons the company spent $68 billion to buy fellow drugmaker Wyeth in 2009 and Pfizer's board forced out CEO Jeffrey Kindler in December 2010.

The pharmaceutical industry is challenged by "lagging R&D productivity and various ongoing/upcoming patent expirations on major drugs across the majority of drug companies," Anderson wrote.

He added that if all the CETP inhibitors and two closely watched drugs being developed to slow progression of Alzheimer's disease also fail, "investor patients could again be tested."

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Uh, sorry Johnnie, but you are incorrect. Despite the assertions by yourself and various defenders and captains, sports attendance is NOT off significantly at most sporting events in the US. Variances in attendance has been in the range of single digits, both + & - for years now. MLB has had most of its best overall attendance nubers in the last decade, and that trend has been consistent for most major sporting events. The number one issue cited by most fans when asked about attendance is the overall cost of attending. The presence of HD and big screen televisions in home doesn't even register, as a factor for not attending an event. VALUE in the product is the key, and apparently is something lacking in the current ICS. What other explanation is there when with what is routinely touted as the "best" racing on the planet, fans are staying away in DROVES. A "close" title battle into the last event at Fontana, with the "cars and stars" of the ICS, and who showed up? MAYBE 8K. Sorry, but HD TV isn't to blame for that kind of fan apathy.

  2. Do you need finance to establish your business ? Are you interested in getting a loan at 3% from our private company? If so please Email: suntrust_oil@blumail.org

  3. If she was worth the $ the public outcry over direct tv dropping them would have kept them on their dishes as we have seen with other companies. I too quit watching channel 13 after she showed up since I left channel 8 because of her all show rather than production results. When Randy on 8 corrected her she had a big head and incorrectly challenged his correction for pronunciation of a city. Other antics while she matures was too much for me with her very inaccurate forecasts. All the forecasters were predicting rain until Thursday except Chris. They predicted sunny on Thursday but instead of rain until Thursday upon which the sun would finally make it out in full glory Chris was right on the money just as I too predicted looking at the radar on weather.gov. One thing I love about Angela is the fear you can see in her every time it thunders in the winter. It far exceeds the entertainment value of her body language (high heel noise drags, depression, etc) when her forecasts are so incorrect. Her hair stands on end, you have to see it!!!

  4. Good Day, Apply For A Loan I am Mr Fernadez Antonio, a private Loan lender and a cooperate financial for real estate and any kinds of business financing. I also offer Loans to individuals, Firms and cooperate bodies at 3% interest rate We offer any kind of loans. email us via fernadezloaninvest@outlook.com LOAN APPLICATION FORM First name:......................... Middle name:......................... Last name:........................................ Date of birth (yyyy-mm-dd):....................... Gender:........................................... Marital status:................................... Total Amount Needed............................... Loan Duration.................................... Address:.......................................... City:............................................. State/province:................................... Zip/postal code:.................................. Country:.......................................... Phone:............................................ Fax:.............................................. Mobile/cellular:.................................. Monthly Income.................................... Occupation:....................................... Best Regard, Mr Fernadez Antonio.

  5. i will love to share my testimony to you all the people in world i got married to my husband about 2 year ago we start having problems at home like we stop sleeping on the same bed,fighting about little things he always comes home late at night,drinking too much and sleeping with other women out side i have never love any man in my life except him. he is the father of my child and i don't want to loose him because we have worked so hard together to become what we are and have today .few month ago he now decided to live me and the kid,being a single mother can be hard sometimes and so i have nobody to turn to and i was heart broken.i called my mom and explain every thing to her,my mother told me about DR.okoro how he helped her solve the problem between her and my dad i was surprise about it because they have been without each other for three and a half years and it was like a miracle how they came back to each other. i was directed to DR. okoro on his email:okorospell@gmail.com and explain everything to him,so he promise me not to worry that he will cast a spell and make things come back to how we where so much in love again and that it was another female spirit that was controlling my husband he told me that my problem will be solved within two days if i believe i said OK So he cast a spell for me and after two days my love came back asking me to forgive him i Am so happy now. so that why i decided to share my experience with every body that have such problem contact Dr okoro the great spell caster on his email addresses spellcasterforlove@outlook.com

ADVERTISEMENT